RHOA and cancer: Previous reports have demonstrated that loss of the ARHGAP42 BAR inhibitory domain is associated with decreased RhoA activity and increased cellular motility in vitro [11], and increased expression of ARHGAP42 in cancer cells is associated with increased cell migration and invasion [21,22].